Hailshadow/iStock via Getty Images Harmony Biosciences ( NASDAQ: HRMY ) said that data from a phase 2 study indicated that its myotonic dystrophy candidate pitolisant reduced excessive daytime sleepiness and fatigue compared to placebo. Results showed that mean improvement on the Daytime Sleepiness Scale, the primary endpoint, from baseline to week 11 was -2.5 for high-dose pitolisant and -1.
0 for the low dose. For placebo, the figure was -0.2.
Pitolisant also met secondary endpoints, such as improvements in fatigue severity and disease burden. Harmony ( HRMY ) said that more than 80% of individuals with myotonic dystrophy Type 1 experience excessive daytime sleepiness and fatigue. More on Harmony Biosciences Harmony Biosciences: Company's Q1 Update Music To Investor Ears (Upgrade) Harmony Biosciences acquires Epygenix gaining rare epilepsy pipeline Harmony Biosciences Non-GAAP EPS of $0.
88 beats by $0.10, revenue of $154.6M misses by $0.
19M Harmony Biosciences Holdings, Inc (HRMY) Q1 2024 Earnings Call Transcript Harmony Biosciences Holdings, Inc. 2024 Q1 - Results - Earnings Call Presentation.
